Ascendis Pharma Reports Results of TransCon Growth Hormone in P-III Height Study for Growth Hormone Deficiency (GHD) in Children

 Ascendis Pharma Reports Results of TransCon Growth Hormone in P-III Height Study for Growth Hormone Deficiency (GHD) in Children

Ascendis Pharma Reports Results of TransCon Growth Hormone in P-III Height Study for Growth Hormone Deficiency (GHD) in Children

Shots:

  • The P-III HEIGHT study involves assessing of Transcon Growth Hormone (hGH) n=105 vs Pfizer’s Genotropin (n=56) in 161 children with GHD in ratio 2:1
  • The P-III HEIGHT study resulting in meeting its 1EPs, non-inferior/superior to Pfizer’s Genotropin, annualized height velocity (AHV) @52 wks. (11.2 cm/yr. vs 10.3 cm/yr.), AEs (1% vs 1.8%), safe & tolerable and presented at ENDO on 24 Mar,2019
  • Transcon hGH (0.24 mg/kg/wk., SC, qw,) is a long acting hGH therapy used to overcome the burden of daily injection on patients with its expected BLA submission in FDA in H1’20

Click here to read full press release/ article | Ref: Ascendis Pharma | Image: Cape Business News

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post